Your browser doesn't support javascript.
loading
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma.
Zuccato, Jeffrey A; Patil, Vikas; Mansouri, Sheila; Liu, Jeffrey C; Nassiri, Farshad; Mamatjan, Yasin; Chakravarthy, Ankur; Karimi, Shirin; Almeida, Joao Paulo; Bernat, Anne-Laure; Hasen, Mohammed; Singh, Olivia; Khan, Shahbaz; Kislinger, Thomas; Sinha, Namita; Froelich, Sébastien; Adle-Biassette, Homa; Aldape, Kenneth D; De Carvalho, Daniel D; Zadeh, Gelareh.
Afiliação
  • Zuccato JA; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Patil V; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Mansouri S; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Liu JC; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Nassiri F; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Mamatjan Y; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Chakravarthy A; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Karimi S; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Almeida JP; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Bernat AL; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Hasen M; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Singh O; Neurosurgery Department, Hôpital Lariboisiere, APHP, Université Paris Diderot, Paris, France.
  • Khan S; Section of Neurosurgery, Division of Surgery, Rady Faculty of Health Science, University of Manitoba, Winnipeg, Canada.
  • Kislinger T; Department of Neurosurgery, King Fahad University Hospital, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Sinha N; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Froelich S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Adle-Biassette H; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Aldape KD; Department of Pathology, Shared Health, HSC, University of Manitoba, Winnipeg, Manitoba, Canada.
  • De Carvalho DD; Neurosurgery Department, Hôpital Lariboisiere, APHP, Université Paris Diderot, Paris, France.
  • Zadeh G; Department of Pathology, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France.
Neuro Oncol ; 24(3): 442-454, 2022 03 12.
Article em En | MEDLINE | ID: mdl-34614192
ABSTRACT

BACKGROUND:

Chordomas are rare malignant bone cancers of the skull-base and spine. Patient survival is variable and not reliably predicted using clinical factors or molecular features. This study identifies prognostic epigenetic chordoma subtypes that are detected noninvasively using plasma methylomes.

METHODS:

Methylation profiles of 68 chordoma surgical samples were obtained between 1996 and 2018 across three international centers along with matched plasma methylomes where available.

RESULTS:

Consensus clustering identified two stable tissue clusters with a disease-specific survival difference that was independent of clinical factors in a multivariate Cox analysis (HR = 14.2, 95%CI 2.1-94.8, P = 0.0063). Immune-related pathways with genes hypomethylated at promoters and increased immune cell abundance were observed in the poor-performing "Immune-infiltrated" subtype. Cell-to-cell interaction plus extracellular matrix pathway hypomethylation and higher tumor purity were observed in the better-performing "Cellular" subtype. The findings were validated in additional DNA methylation and RNA sequencing datasets as well as with immunohistochemical staining. Plasma methylomes distinguished chordomas from other clinical differential diagnoses by applying fifty chordoma-versus-other binomial generalized linear models in random 20% testing sets (mean AUROC = 0.84, 95%CI 0.52-1.00). Tissue-based and plasma-based methylation signals were highly correlated in both prognostic clusters. Additionally, leave-one-out models accurately classified all tumors into their correct cluster based on plasma methylation data.

CONCLUSIONS:

Here, we show the first identification of prognostic epigenetic chordoma subtypes and first use of plasma methylome-based biomarkers to noninvasively diagnose and subtype chordomas. These results may transform patient management by allowing treatment aggressiveness to be balanced with patient risk according to prognosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article